Skip to main content

Paradoxical low severity of COVID-19 in Prader-Willi syndrome: data from a French survey on 647 patients



Patients with Prader-Willi syndrome (PWS) often have comorbidities, especially obesity, that may constitute a risk factor for severe forms of COVID-19. We aimed to assess prevalence and medical course of SARS-CoV-2 infection in children and adults with PWS. From November 2020 to January 2021, we performed a detailed medical survey on 342 adults and 305 children with PWS followed in the French reference center.


We obtained responses from 288 adults (84%) and 239 children (78%). From March 2020 to January 2021, 38 adults (13.2%) and 13 children (5.4%) with PWS had SARS-CoV-2 infection. Mean age of adults was 34.1 ± 11.9 years and mean body mass index was 40.6 ± 12.7 kg/m2; 82% had obesity and 37% had diabetes. Only 3 children (23%) had obesity and none had diabetes. Similar to the general population, the most frequent symptoms of COVID-19 were asthenia, fever, cough, headache and shortness of breath. All patients had a favorable outcome.


PWS itself is not a risk factor for severe COVID-19 in children and adults. On the contrary, evolution of SARS-CoV-2 infection in adults with PWS seems more favorable than expected, given their comorbidities.


Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by loss of expression of paternal-origin imprinted alleles on chromosome 15q11-q13. Paternal deletion is found in about 60%, maternal uniparental disomy (UPD) in 36% and imprinting defects in 4% [1]. Impaired hypothalamic development is the cause of the complex PWS phenotype: from anorexia at birth to early obesity with hormonal deficiencies and behavioral problems [2].

In contrast to the extensive literature on obesity contributing to increased risk of severe COVID-19 [3, 4], there is no published report concerning the course of COVID-19 in PWS, the most common form of syndromic obesity with an incidence of approximately 1 in 21,000 newborns [5]. In May 2020, the International Prader-Willi Syndrome Organization (IPWSO) launched a survey and the first results on June 8 showed a majority of mild infections [6]. These early data were surprising given that adults with PWS often present comorbidities which can negatively impact outcomes of COVID-19 [4]. In addition, patients with PWS have difficulties in expressing complaints and decreased fever when infection occurs, which can delay diagnosis [7]. Finally, the risk of SARS-CoV-2 infection is increased in adults with PWS because many of them live in a community structure and social distancing can be difficult in adults with intellectual and developmental disability (IDD).

We thus performed a medical survey among the patients routinely followed in the French reference center of PWS in order to assess the incidence and medical characteristics (type of signs and symptoms, severity) of the COVID-19 in patients with PWS, in addition to our participation in the IPWSO survey.


Characteristics of adults with PWS and COVID-19

Two hundred and eighty-eight responses were obtained from the 342 families contacted (84%). Among the 288 adults, 38 (13.2%) had a confirmed COVID-19 between March 2020 and January 2021 (Table 1). Mean age was 34 years, 58% were female, 89% were Caucasian and 53% had deletion. Most patients had obesity (82%) including 55% with severe obesity. Half of the patients were living in a residential group home at the time of infection. Ten patients were hospitalized when infection occurred: one for erysipelas and 9 in Hendaye hospital (cluster).

Table 1 Cases of COVID-19 in French adults with Prader-Willi syndrome between March 2020 and January 2021

About 60% of patients were on vitamin D supplementation at the time of infection. Most patients were taking psychotropic treatments including antipsychotics and antidepressants in a half and one third of the cases, respectively.

Medical characteristics of COVID-19 in adults with PWS

Symptoms of COVID-19 were common but only one adult reported anosmia, and 37% were asymptomatic (Table 1). Three adults were hospitalized for pneumonia confirmed by computed tomography and requiring oxygen administration for all and dexamethasone for one.

The nine other hospitalized adults were part from a cluster in the PWS rehabilitation unit of Hendaye Hospital (Table 2). Like all hospitalized patients, the patient at the origin of the cluster had a negative RT-PCR 72 h before admission, but was contaminated by her caregiver during the travel to the hospital. She refused to wear a mask, which led to the contamination of 8 other patients in a unit with women only. Mean age was 38.2 years. Five patients (55%) had numerous comorbidities including massive obesity (BMI ≥ 40 kg/m2) for all, and type 2 diabetes, hypertension, sleep apnea syndrome, respiratory failure, lower limbs edema and past venous thrombotic events for most of them. Two patients had a pneumonia confirmed by chest X-ray and requiring oxygen administration, dexamethasone and antibiotics (Table 2). Evolution was favorable with rapid full recovery in all symptomatic patients (Table 1).

Table 2 Characteristics of the 9 patients of the Hendaye’s cluster

COVID-19 survey in children with PWS

Two hundred and thirty-nine responses were obtained from the 305 families contacted (78%). Among the 239 children, 13 (5.4%) had COVID-19 (Table 3).

Table 3 Cases of COVID-19 in French children with Prader-Willi syndrome between March 2020 and January 2021

Mean age was 9.6 years, 38% were female, 85% were Caucasian and 62% had deletion. Three children (23%) had obesity and two had sleep apnea syndrome. All children were living at home with family at the time of infection.

Most children (85%) were on vitamin D supplementation and only one had a psychotropic treatment (neuroleptics) at the time of infection. Three quarters of children were symptomatic but only one reported anosmia. The evolution of symptomatic cases was favorable without hospitalization and total recovery occurred in 92% of patients. One child had persistent asthenia several months after infection.


To our knowledge, this is the first study regarding medical characteristics of COVID-19 in patients with PWS, as reported in De Groodt et al. [9]. The two other studies concerning the COVID-19 pandemic and PWS reported behavioral and physical changes in people with PWS during the pandemic, but not medical outcomes of patients with COVID-19 [10, 11].

In France, the estimated proportion of people with SARS-CoV-2 infection, based on the fact that about 3% of patients with COVID-19 are hospitalized, had already reached 11.3% in November 2020 and up to 21.3% in the Ile-de-France region [12]. According to these estimates, adults with PWS were not more infected (13.2% of the cohort) than the French general population as of January 31, 2021. Regarding children, we do not have French data to compare, but we notice a low prevalence of COVID-19 in our cohort (5.4%).

The most important finding of our study is that we did not report any serious form of COVID-19 in adults despite many comorbidities, especially obesity and diabetes. The young age of our patients (mean of 34 years) can explain this finding since age is the main known risk factor for severe COVID-19 [4]. It is difficult to compare the severity of COVID-19 in our cohort to the French general population, including hospitalization rate for COVID-19 which is estimated at about 0.5% for people between 30 and 40 years in France [13] because 10 patients with PWS (26%) were already hospitalized (including 9 in the Hendaye hospital rehabilitation center) when infection occurred.

In contrast to our findings, several studies have reported a higher mortality due to COVID-19 in patients with Down syndrome compared to general population [14, 15]. In an international survey of 1,046 patients with a mean age to 29 years, COVID-19 severity and mortality were higher, even below 40 years, compared to the general population [15]. This poor prognosis can be explained by an immune-response dysfunction in Down syndrome, while immune function does not seem to be altered in PWS (no higher infection predisposition in our routine clinical practice). In addition, several studies have reported a higher mortality in patients with IDD compared to general population, especially in those living in residential group homes [16]. Thus, it was surprising that French adults with PWS, half of whom who were living in a residential group home, not only did not develop severe COVID-19 but also had a quick recovery.

In addition to the young age of our adults’ cohort, another hypothesis explaining the absence of severe COVID-19 in adults with PWS could be the beneficial role of oxytocin (OXT). Indeed, OXT, a neuropeptide produced in the hypothalamic paraventricular nucleus and supraoptic nucleus, is an immune-regulating neuropeptide, which has recently emerged as a candidate for treatment and prevention of COVID-19 [17,18,19]. OXT seems to carry special functions in immunologic defense: it suppresses neutrophil infiltration and inflammatory cytokine release, activates T-lymphocytes, and antagonizes negative effects of angiotensin II and other key pathological events of COVID-19 [19]. Through these mechanisms, OXT can block viral invasion, suppress cytokine storm, reverse lymphocytopenia, and prevent progression to severe COVID-19 [17,18,19]. OXT system is impaired in most patients with PWS [2] and the high plasmatic levels of OXT (possibly due to overcompensation of a brain deficit) in patients with PWS could play a protective role against COVID-19.

Other hypotheses are the potential protective effects of the drugs taken by our patients. In addition, most of our patients were treated with vitamin D which could have a protective role against COVID-19 [20, 21] even if there is no consensus on the reduction of the risk of severe evolution of COVID-19 in patients without deficit in a meta-analysis [22]. Moreover, a third of adults with PWS in our cohort were on antidepressants, that may have a beneficial effect on the course of COVID-19 [23, 24]. Finally, 10 adults with diabetes took Metformin (83% of diabetics) which reduced the mortality of hospitalized patients with COVID-19 and type 2 diabetes in several studies [25,26,27], but it is difficult to know if Metformin is a witness of less severe diabetes or if it has a specific effect on COVID-19 in these studies. Thus, the potential protective effects of these molecules are only hypotheses that should be interpreted with caution.

Our study has limitations. The main limitation is that we did not extend the survey to all families of patients with PWS in France because we were aiming for a medical investigation in patients followed in the reference center. Thus, the survey concerned over 600 families out of about 1000 families with PWS in France. However, patients followed in the reference center are usually the most severe [28], and we are not aware of severe COVID-19 in other French patients with PWS. The second limitation is that not all of the COVID-19 cases in children were confirmed, since children testing were not usually performed in France during this period.


Despite many risk factors for severe COVID-19, such as obesity and diabetes, French adults with PWS only had mild or moderate COVID-19. The main explanation is their young age (34 years) and possibly other protective mechanisms that have yet to be elucidated. Thus, PWS itself cannot be considered as a risk factor for severe COVID-19.


Study rational and design

Between November 2020 and January 2021, 647 families of children and adults with genetically confirmed PWS and followed in the 3 sites of the French reference center (Paris Pitié Salpêtrière and Necker, Hendaye, and Toulouse hospitals) were contacted by telephone and/or e-mails. The PWS diagnosis was genetically confirmed before the survey using routine genetic laboratory methods. First, we performed DNA-based methylation testing to detect the absence of the paternally contributed PWS region on chromosome 15q11-q13 at locus SNRPN (Small Nuclear Ribonucleoprotein Polypeptide N). Secondly, molecular mechanism was clarified using a standard fluorescence in situ hybridization (FISH) to detect a deletion. If no deletion was found, analysis of parental and proband DNA with microsatellites was performed to confirm maternal UPD.

A confirmed COVID-19 was defined as a positive Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) from a nasopharyngeal swab or the presence of blood antibodies against SARS-CoV-2 after infection. A suspected COVID-19 was defined as reporting symptoms of COVID-19 and close contact with a confirmed COVID-19 case in the 14 days prior to onset of symptoms [8].

When a case of COVID-19 was reported, a detailed medical questionnaire was filled by a clinician from the center of reference and medical records were consulted. All participants of this study (patients and caregivers) were informed and gave their oral consent for participation in this study and publication of the results.

Statistical analysis

Data are expressed as means ± SD or numbers (%). We used descriptive statistics to report the demographic information and medical data of the patients with COVID-19.

Availability of data and materials

Muriel Coupaye, Virginie Laurier and Fabien Mourre have stored all the data, which are available upon reasonable request.


  1. 1.

    Butler MG, Hartin SN, Hossain WA, et al. Molecular genetic classification in Prader-Willi syndrome: a multisite cohort study. J Med Genet. 2019;56:149–53.

    CAS  Article  Google Scholar 

  2. 2.

    Tauber M, Hoybye C. Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction. Lancet Diabetes Endocrinol. 2021;26:S2213-8587(21)00002-4.

    Google Scholar 

  3. 3.

    Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21(11):e13128.

    CAS  Article  Google Scholar 

  4. 4.

    Li Y, Ashcroft T, Chung A, et al. Risk factors for poor outcomes in hospitalised COVID-19 patients: a systematic review and meta-analysis. J Glob Health. 2021;1(11):10001.

    Article  Google Scholar 

  5. 5.

    Bar C, Diene G, Molinas C, Bieth E, Casper C, Tauber M. Early diagnosis and care is achieved but should be improved in infants with Prader-Willi syndrome. Orphanet J Rare Dis. 2017;12(1):118.

    Article  Google Scholar 

  6. 6.

    IPWSO. Early results from IPWSO’s PWS and COVID-19 survey (2020). Accessed 15 Mar 2021.

  7. 7.

    Muscogiuri G, Formoso G, Pugliese G, Ruggeri RM, Scarano E, Colao A. RESTARE Prader-Willi syndrome: an uptodate on endocrine and metabolic complications. Rev Endocr Metab Disord. 2019;20(2):239–50.

    Article  Google Scholar 

  8. 8.

    European Center for Diseases Control. Case definition for coronavirus disease 2019 (COVID-19), as of 3 December 2020. Accessed 24 Mar 2021.

  9. 9.

    De Groot CJ, Poitou Bernert C, Coupaye M, et al. Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity. Endocrine. 2021;29:1–10.

    Google Scholar 

  10. 10.

    Mosbah H, Coupaye M, Flavien J, et al. Effects of the COVID-19 pandemic and lockdown on the mental and physical health of adults with Prader-Willi Syndrome. Orphanet J Rare Dis. 2021;16(1):202.

    Article  Google Scholar 

  11. 11.

    Wieting J, Eberlein C, Bleich S, Frieling H, Deest M. Behavioural change in Prader-Willi syndrome during COVID-19 pandemic. J Intellect Disabil Res. 2021;65(7):609–16.

    CAS  Article  Google Scholar 

  12. 12.

    Institut Pasteur. COVID-19 modelling. Accessed 3 Apr 2021.

  13. 13.

    Lapidus N, Paireau J, Levy-Bruhl D, et al. SAPRIS-SERO study group Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population. Infect Dis Now. 2021;51(4):380–2.

    Article  Google Scholar 

  14. 14.

    Emami A, Javanmardi F, Akbari A, Asadi-Pooya AA. COVID-19 in patients with Down syndrome. Neurol Sci. 2021;1:1–4.

    Google Scholar 

  15. 15.

    Hüls A, Costa ACS, Dierssen M, et al. T21RS COVID-19 Initiative. Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey. E Clin Med. 2021;2021:100769.

    Google Scholar 

  16. 16.

    Landes SD, Turk MA, Formica MK, McDonald KE, Stevens JD. COVID-19 outcomes among people with intellectual and developmental disability living in residential group homes in New York State. Disabil Health J. 2020;13(4):100969.

    Article  Google Scholar 

  17. 17.

    Soumier A, Sirigu A. Oxytocin as a potential defence against Covid-19? Med Hypotheses. 2020;140:109785.

    CAS  Article  Google Scholar 

  18. 18.

    Diep PT, Talash K, Kasabri V. Hypothesis: oxytocin is a direct COVID-19 antiviral. Med Hypotheses. 2020;145:110329.

    CAS  Article  Google Scholar 

  19. 19.

    Wang SC, Wang YF. Cardiovascular protective properties of oxytocin against COVID-19. Life Sci. 2021;270:119130.

    CAS  Article  Google Scholar 

  20. 20.

    Charoenngam N, Shirvani A, Reddy N, Vodopivec DM, Apovian CM, Holick MF. Association of vitamin D status with hospital morbidity and mortality in adult hospitalized COVID-19 patients. Endocr Pract. 2021;8:S1530-891X(21)00057-4.

    Google Scholar 

  21. 21.

    Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. J Infect Public Health. 2020;13(10):1373–80.

    Article  Google Scholar 

  22. 22.

    Liu N, Sun J, Wang X, Zhang T, Zhao M, Li H. Low vitamin D status is associated with coronavirus disease 2019 outcomes: a systematic review and meta-analysis. Int J Infect Dis. 2021;104:58–64.

    CAS  Article  Google Scholar 

  23. 23.

    Hoertel N, Sánchez-Rico M, Vernet R, et al. AP-HP/Universities/INSERM COVID-19 Research Collaboration and AP-HP COVID CDR Initiative. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021.

  24. 24.

    Pashaei Y. Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives? J Clin Neurosci. 2021;88:163–72.

    CAS  Article  Google Scholar 

  25. 25.

    Lukito AA, Pranata R, Henrina J, Lim MA, Lawrensia S, Suastika K. The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14(6):2177–83.

    Article  Google Scholar 

  26. 26.

    Hariyanto TI, Kurniawan A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection. Obes Med. 2020;19:100290.

    Article  Google Scholar 

  27. 27.

    Kow CS, Hasan SS. Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis. J Med Virol. 2021;93(2):695–7.

    CAS  Article  Google Scholar 

  28. 28.

    Laurier V, Lapeyrade A, Copet P, et al. Medical, psychological and social features in a large cohort of adults with Prader-Willi syndrome: experience from a dedicated centre in France. J Intellect Disabil Res. 2015;59(5):411–42.

    CAS  Article  Google Scholar 

Download references


We thank Mariam Hamouli and Sandy Faye for their help in the survey. We also thank the patients and families/caregivers for agreeing to participate in the survey.



Author information




MC, MT and FM designed the study. All authors contributed to patient recruitment and performed the clinical survey. MC, VL and FM analyzed the data and wrote the manuscript. MC, VL, CP, MT, and FM contributed to the data presentation and editing of the manuscript. All authors reviewed the manuscript. MC is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Muriel Coupaye.

Ethics declarations

Ethics approval and consent to participate

Patients and their caregivers provided oral informed consent.

Consent for publication

All authors reviewed and approved the final article.

Competing interests

None of the authors declare a conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Coupaye, M., Laurier, V., Benvegnu, G. et al. Paradoxical low severity of COVID-19 in Prader-Willi syndrome: data from a French survey on 647 patients. Orphanet J Rare Dis 16, 325 (2021).

Download citation


  • Prader-Willi syndrome
  • COVID-19
  • SARS-CoV-2
  • Obesity
  • Oxytocin